

## **Zydus scores with the Day 1 launch of Zolmitriptan in the US**

Ahmedabad, 16 May 2013

Zydus Cadila announced the Day 1 launch of Zolmitriptan orally disintegrating tablets upon receiving the final approval from the US FDA. The Company is marketing the product in the strengths of 2.5 mg and 5mg in the US market. The sales of Zolmitriptan, used in the treatment of migraine, was estimated at USD 175 million in 2012 as per IMS.

The group now has 79 approvals and has so far filed 173 ANDAs since the commencement of the filing process in FY 2003-04.

\*\*\*